Physician profile
David E Pruett
NPI 1396956165
$871.34
in general payments reported to CMS, 2019-2025
11 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2022: $104 · 2023: $241 · 2024: $113 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468 · Education: $62.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.27 |
| Education | $62.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.54 | 2022-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $141.66 | 2019-2025 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $100.55 | 2023-2024 | |
| Fresenius USA Marketing, INC. | $96.73 | 2019-2024 | Velphoro, Korsuva |
| Amgen INC. | $73.87 | 2019-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $56.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.68 | 2025 | |
| Calliditas Therapeutics US INC. | $42.14 | 2025 | Tarpeyo |
| Vifor Pharma, INC. | $22.31 | 2024 | |
| Akebia Therapeutics INC | $14.98 | 2024 | Vafseo, Auryxia |
| Ardelyx, INC. | $14.53 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pruett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.